Through 2032, the preimplantation genetic testing market is anticipated to develop at a CAGR of around 9% and reach a significant market size. Growth opportunities are expanding as a result of the rising prevalence of genetic illnesses. The market is anticipated to reach US$ 653.52 million by 2022 and will continue to grow, reaching US$ 1,420 million by 2032. Download Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=292 The biggest benefit offered by preimplantation testing is it offers an opportunity to conceive a pregnancy unaffected by genetic conditions. Researchers and healthcare institutes are trying to find new methods and techniques using the latest technology to minimize various risks associated with preimplantation genetic testing. Key Highlights Global demand for genetic screening to gain 2/3rd market share through 2032. Maximum application found in embryo HLA typing for stem cell therapy, yielding 40% revenue. North America remains the highest consumer, contributing a CAGR of around 7% U.K contributing to the bulk of preimplantation genetic testing market expansion, growing at a CAGR of 8% India and China to collectively generate around 60% of demand across Asia through 2032 NGS is likely to emerge as the most popular technology, surpassing US$ 200 Million in revenue Competitive Landscape The global market is highly fragmented with the presence of a large number of local and regional players. Market players are concentrating on product launches to broaden their market footprints. In May 2021, United Airlines and Abbott Laboratories announced a collaboration to use Abbott’s BinaxNOW™ COVID-19 Home Test and Abbott’s NAVICA app to help make the international travel experience more seamless. In March 2021, Agilent Technologies Inc., entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. In June 2021, Thermo Fisher Scientific and First Genetics JCS, a manufacturer of diagnostic equipment and IVD kits intended to advance molecular genetic technologies into clinical practice, today announced a strategic partnership focused on commercializing next-generation sequencing (NGS)–based diagnostics in Russia. The agreement enables First Genetics to market its F-Genetics NGS System and IVD assays to Russian labs for reproductive health testing and cancer diagnostics. The F-Genetics System is based on Thermo Fisher’s Ion GeneStudio S5 System. Market Titans Agilent Technologies Inc. Abbott Laboratories CooperSurgical Inc. Oxford Gene Technology IP Illumina Inc. Thermo Fisher Scientific Inc. PerkinElmer Inc. Genea Limited Natera Inc. Rubicon Genomics Inc. CombiMatrix Corporation Workflow Optimization By Test Type: Preimplantation Genetic Diagnostics Preimplantation Genetic Screening By End User: Hospitals Diagnostic Labs Research & Academic Institutions Specialized Clinics Preimplantation Genetic Testing by Other End Users By Application: Embryo HLA Typing for Stem Cell Therapy IVF Prognosis Late-Onset Genetic Disorders Inherited Genetic Diseases Other Applications By Technology: NGS-based Preimplantation Genetic Testing PCR-based Preimplantation Genetic Testing FISH-based Preimplantation Genetic Testing CGH-based Preimplantation Genetic Testing SNP-based Preimplantation Genetic Testing By Region: North America Latin America Europe Japan APEJ Middle East Africa Increasing Prevalence of Genetic Screening across Specialized Clinics to Fuel Global Demand According to the Centers for Disease Control and Prevention (CDC), chronic ailments such as cancer, heart disorders, and diabetes are the leading cause of disability and death in people across the United States. Every year, the nation’s healthcare system spends close to US$ 3 billion on direct and indirect expenses. Additionally, it is anticipated that in the upcoming years, market expansion would be aided by healthcare professionals’ growing awareness of the efficacy of genetic testing techniques. Get Customization on this Report for Specific Research Solution- https://www.factmr.com/connectus/sample?flag=RC&rep_id=292
Last changed by  
 
Factmrsurvey
29

Read more

Untitled

By the end of 2033, the chronic idiopathic constipation treatment market is expected to have grown from a projected value of US$ 9.4 billion in 2023 to US$ 19.7 billion, expanding quickly at a CAGR of 7.5%. When a person has difficult, infrequent, and/or suboptimal defecation, it is known as chronic idiopathic constipation (CIC), a common functional bowel disorder. Chronic idiopathic constipation is becoming more common due to factors like sedentary lifestyles, growing anti-inflammatory medicine use, and a rapid decline in dietary fibre consumption. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8517 Additionally, rising rate of the ageing population, sedentary lifestyles, and dietary changes are contributing to the increasing burden of CIC, thereby driving the demand for treatment options. Fiber supplements, laxatives, stool softeners, and prokinetic agents are commonly used as medications in the management of CIC. Furthermore, advancements in digital health technologies are also shaping the future of chronic idiopathic constipation treatment. Mobile applications, wearable devices, and remote monitoring tools are being developed to help patients track their bowel movements, diet, and exercise habits, and provide personalized recommendations for managing CIC.

8/7/2023
Untitled

The Automotive Ceramics Industry sales study offers a comprehensive analysis on diverse features including production capacities, Automotive Ceramics demand, product developments, sales revenue generation and Automotive Ceramics market outlook across the globe. 170 page market research report by Fact.MR, (Leading business and competitive intelligence provider) on global Automotive Ceramics market sales initiates with an outlook of the market, followed by the scrutiny of the demand and consumption volumes and share and size of various end-use segments The global automotive ceramics market was valued at US$ 2.3 Billion in 2021 and market is valued at US$ 2.42 Billion in 2022 During the 2022-2032 period of assessment, demand is expected to rise at a 5.4% value CAGR, likely to reach US$ 6.6 Billion by the end of the said forecast period. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=6406 The readability score of the Automotive Ceramics market demand report is good as it offers chapter-wise layout with each section divided into a smaller sections.

8/7/2023
Global Implantable Medical Devices Market Is Predicted To Reach US$ 155 Billion By 2027

According to Fact.MR’s most recent industry analysis, implanted medical device market sales are expected to grow globally between 2022 and 2027 at a compound annual growth rate of 6.1%. The market for implantable medical devices is expanding as a result of increased chronic illness prevalence, an ageing population, and improvements in active implanted medical devices. Additionally, increased funding and investments in the creation of technologically advanced products, elevated awareness of advancements in medical implants, and an increase in the use of neurostimulators are all contributing to market expansion. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7728 Incidence of cardiovascular diseases is rising, and obesity rates are high, which are the main drivers that are likely to fuel market growth for implantable medical devices. Medical professionals and patients can monitor their illnesses to receive an early update with the use of implantable medical devices. These wireless, automated devices assess a patient’s sensitivity to a prescribed medicine dosage. The rising prevalence of neurological illnesses such as Parkinson’s disease and spasticity is driving the demand for active implantable medical devices.

8/7/2023
Worldwide Shipments of Anesthesia Monitoring Devices are Anticipated to Increase at an Impressive CAGR of 9.1% by 2032

Anaesthesia monitoring equipment market sales are anticipated to grow globally between 2022 and 2027 at a strong CAGR of 9.1%. The market for anaesthesia monitoring devices is currently worth US$ 2.2 billion. Since there has been a noticeable rise in the prevalence of chronic diseases, more surgeries are being conducted, which increases the demand for anaesthesia apparatus, including anaesthesia monitoring devices. A growing elderly population, rising healthcare costs, and product technology developments are further variables that may boost demand for anaesthesia monitoring devices. The expensive cost of anaesthesia monitoring equipment, however, is anticipated to limit market potential to some degree. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7683 Anesthesia monitoring device manufacturing companies are focusing on the expansion of their product portfolios and are also expanding their business scope by gaining new approvals from regulatory authorities. In April 2022, GE Healthcare, a leading name in the medical industry, announced that it had received pre-market approval from the U.S. FDA for its new software to deliver general anesthesia. The End-Tidal (Et) Control software is cleared to be used on GE’s Aisys CS2 Anesthesia Delivery System.

8/7/2023
Read more from Factmrsurvey
Published on HackMD